BRANDED GENERICS: NEW AVENUE FOR RX EXPANSION INTO EMERGING
MARKETS FEBRUARY 27-28, 2012
HUB CIRA CENTER IN PHILADELPHIA, PA
D A I S Y R I V E R A - M U Z Z I O , R . P H , M S , M B A P R E S I D E N T
A C U M E N B I O P H A R M A , L L C
Business, IP, and Clinical Strategies for Expansion into
Latin America with Branded Generics
Panel Members
Elias Rios Navarro-Intellectual Property - Arochi, Marroquin& Lindner - Mexico
Ana Claudio Mamede- Intellectual Property - Danneman Siemsen, Biger & Ipanema Moreira - Brazil
Janet Mora-Regulatory & Marketing – Link Pharma
Woody Bryan - Business Development - Supernus Pharmaceuticals
Daisy Rivera-Muzzio - Business Development & Intellectual Property -Acumen BioPharma
What is a branded generic in the US?
Off Patent drug molecule
New Dosage form
Differentiated drug delivery system
New Product Strength
New combination of API’s
Intellectual property
Formulation /Manufacturing Process
Components
New Indication(s)
Technology
Method of Use
Regulatory
NDA- 505 (b) (2)
Clinical studies to support label information
3-5 years market exclusivity
A novel invention
3
February 27-28, 2012
Differences between Branded vs. Commoditized Generics
February 27-28, 2012
Require clinical studies
Not necessarily bioequivalent to the innovator
Distribution channels- Requires commercial promotional strategies
Premium Price
More expensive development
Proprietary technology
May have market exclusivity 3-5 years
It is NOT an Authorized Generic
Branded generics: Rest of the world
¡ Value added or Branded generics also exists in the rest of the world, different regulations applied and a real benefit to the patient must be proven to get premium price approval in those countries with drug product price regulations
¡ A generic product can be commercialized under a brand or trade name following retail promotion strategies similar to those of innovator products. Examples: Greece, France, Spain, Eastern EU, Latin America
February 27-28, 2012
FDA and UK’s National Health Services ( NHS) Definition of Branded Generics
“Prescription products that are either
1) novel dosage forms of off-patent products produced by a manufacturer that is not the originator of the molecule,
or
2) a molecule copy of an off-patent product with a trade name”.
February 27-28, 2012
Examples of Branded Generics- US
Intermezzo offers a new dosage form, new strengths and new indication for off patent molecule-(middle of the night awakening)
Tirosint is the first and only T4 therapy in a liquid gel cap formulation
The NitroMist Aerosol Delivery System Unique aerosol delivery system that maintains the potency and stability of nitroglycerin for up to 36 months (or approximately 230 sprays)
Suprenza is the first and only orally disintegrating tablet(ODT) phentermine formulation.
February 27-28, 2012
Generic Evolution
� “The generics makers that will grow most are those that focus on higher-tech formulations and specialty drugs, rather than the easily commoditized tablets and capsules common in primary care. The trend is shifting towards less competitive, yet commercially attractive segments such as difficult-to-produce generics, specialty generics and biosimilars.”
Frost & Sullivan
8
February 27-28, 2012
Source: EMC managers, BSCH, BBVA, JPM, DB 9
Global Growth - 2003-2012E(%)
February 27-28, 2012
10
2008 sales $28.8 bn
$11.4 bn
$7.8 bn
$3.0 bn
$4.0 bn Expected growth >70% in 5 years: • Launch of new products, • Increased out of pocket
spending • Public demand for quality
pharmaceuticals Steady population growth of 1%, and a balanced sex ratio 10 % of the population is over 60 years old Non-communicable diseases especially neuropsychological and CVS disorders cause more casualties in LA than communicable diseases
Resistors to growth: • Compulsory Licensing ( Brazil) • Intellectual property Annulment
( Venezuela) • Prohibition of use of second patents Characteristics of generic drug policy in Latin America: • Lack of separate generic approval protocol • Absence of a link between patent and
regulatory agencies impedes the flow of knowledge regarding the authorization of infringing products;
• Lack of sufficient data exclusivity enables generic players to access clinical data for development of generics;
• Bioequivalence is not a mandatory requirement for generic approval in many Latin American countries
• Drug pricing Regulated by Government agencies
Gro
wth
Opp
ortu
niti
es
Resistors to grow
th
Latin America, Pharmaceutical Market
February 27-28, 2012
11
Country-wise sales Forecasts, 2008-2014
February 27-28, 2012
Latin America Pharmaceutical Market Outlook to 2014- Business insight
12
Forecast Sizes of Latin American Markets
February 27-28, 2012
Latin America Pharmaceutical Market Outlook to 2014- Business insight
13
SWOT - Latin American Regulatory Landscape
February 27-28, 2012
Latin America Pharmaceutical Market Outlook to 2014- Business insight
14
Clinical Trials in Latin America
February 27-28, 2012
Latin America Pharmaceutical Market Outlook to 2014- Business insight
15
PhRMA Special 301 submission regarding Latin America, 2009
Latin America Pharmaceutical Market Outlook to 2014- Business insight
Panel Discussion
� Discovering opportunities in the Latin American markets for branded generics drugs
� Comparing IP and patent compliance in Latin America vs. the United States
� Filling the gaps in the approval process for clinical trial initiated in Latin America
Daisy Rivera-Muzzio
Janet Mora Woody Brian
Ana Claudia Mamede Carneiro
Elias Rios Navarro
Acumen BioPharma Moderator
Link Pharma Regulatory & Marketing
Supernus Business Development
Dannemann-Siemsen, Bigler & Ipanema Moreira Intellectual Property- Brazil
Arochi, Marroquin& Lindner Intellectual Property- Mexico
16
Panel Discussion
• WHAT IS THE MARKET OPPORTUNIT Y FOR BRANDED GENERICS IN L ATIN AMERICA ?
• WHAT ARE THE RISKS ASSOCIATED WITH BRINGING A PATENTED PROTECTED PRODUCT IN LATIN AMERICA
• WHAT ARE THE STRATEGIES TO HAVE A SUCCESSFUL COMMERCIALIZATION OF THESE PRODUCTS IN LA?
•
February 27-28, 2012
Intellectual Property Assessment for Branded Generics in Mexico
Elias Rios Navarro
Mexico.-‐ Marke5ng Authoriza5on
API Patent Expired
Secondary Patent
API Special forms
Linkage
Pharm Composi@on
Linkage by li@ga@on
Process No linkage
Marke@ng Authoriza@on Granted to No patent holder
In force
Sales Preliminary Measures
IP infringement Before MX PTO
No nullity Infringement
Damages Lost Profits 40%> + Fine
Cancelled
Bond
Counterbond
Sales Nullity Trial / Const. Action
PTO Decision
No nullity No Infringement
Nullity No Infringement
Execu@on of the bond
Counter claim
Civil Courts
dannemann.com.br © 2012 Dannemann Siemsen. All rigths reserved. 20
BRANDED GENERICS: New Avenue for Rx Expansion Into Emerging Markets
February 27-‐28, 2012 Hub Cira Center in Philadelphia, PA
Intellectual Property Issues
Ana Claudia Mamede Carneiro
© 2012 Dannemann Siemsen. All rights reserved.
dannemann.com.br © 2012 Dannemann Siemsen. All rigths reserved. 21
BRAZIL -‐ Prosecu@on of patent cases § Steps:
§ Request for examina5on: 3 years from filing date § Third par5es may file a pre-‐grant opposi5on § If allowed by PTO, for pharmaceu5cal cases, the applica5on will be sent to ANVISA (Sanitary Agency) for prior consent:
• If ANVISA allows, the case will return to PTO (final fees) • If ANVISA rejects, …
§ If rejected by PTO, an appeal is applied • If the PTO allows, the case will be sent to ANVISA for prior consent
• If the PTO rejects, the administra5ve instance will be ended § Third par5es may file a post-‐grant opposi5on
dannemann.com.br © 2012 Dannemann Siemsen. All rigths reserved. 22
BRAZIL -‐ Prosecu@on of patent cases
§ Backlog of 8-‐10 years for the publica5on of a first technical opinion
§ No difference between the different technical fields
dannemann.com.br © 2012 Dannemann Siemsen. All rigths reserved. 23
BRAZIL -‐ Prosecu@on of patent cases
q Patent Office hired approximately 350 new examiners
q Faster prosecu5on expected
q Fast track q Poten5al infringement cases (warning le[er to the alleged infringer)
q Ar5cle 40 of IP law – Minimum 10 year patent term as of grant
dannemann.com.br © 2012 Dannemann Siemsen. All rigths reserved. 24
BRAZIL -‐ ANVISA’s prior consent
q Provisional Measure # 2006 of Dec 14, 1999
q Law # 10,196 of Feb 14, 2001
q Art. 229-‐C of the IP Law 9279/96
§ “grant of patents to pharmaceu5cals products and processes are subject to prior approval by ANVISA”
dannemann.com.br © 2012 Dannemann Siemsen. All rigths reserved. 25
BRAZIL -‐ Prior approval (ANVISA)
q Since 2003 examining substan5ve patentability criteria
q Grounds for non-‐approval
q lack of novelty and/or inven5ve step
q lack of enablement
q addi5on of new ma[er
q second use = discovery
q mandatory restric5on of scope of Markush-‐type claims
dannemann.com.br © 2012 Dannemann Siemsen. All rigths reserved. 26
BRAZIL -‐ Recent Developments (ANVISA)
q A[orney General’s Office (AGU) Opinions (2011)
q Recent decision from the Federal Court of Brasília
“The men(oned rule [art. 229-‐C] is uncons(tu(onal since it wrongfully revokes ar(cle 4 quarter of the Paris Union Conven(on, lacking reasonability, and also duplicates the technical examina(on for patentability unnecessarily and unreasonably, a rule that is both internal and conven(onal and that executes a cons(tu(onal order to protect patent rights as a fundamental guarantee.”
(Astrazeneca v. ANVISA and BPTO – Court Ac5on n.29724-‐20.2010.4.01.3400, 01.12.2011, 8th Federal Court)
dannemann.com.br © 2012 Dannemann Siemsen. All rigths reserved. 27
ANVISA’s recent publications
DOU 04.07.2011 DOU 07.10.2011 DOU 07.11.2011
Total 23 41 8
Approval 13 41 8
Straight 13 35 2
After rebuttal 0 3* 0
After compliance of office action 0 1 2
After appeal 0 2 4
Rejection 10 0 0
* 1) lack of enablement (Article 25 - IPL); 2) lack of inventive step (Article 13 - IPL); e 3) restriction to the content of the examples (Articles 24 and 25 - IPL)
dannemann.com.br © 2012 Dannemann Siemsen. All rigths reserved. 28
BRAZIL – Non-‐patentable maders
§ Non-‐patentable
§ Therapeu5c, surgical and diagnos5c methods applied to human or animal bodies
§ Living beings and parts thereof, including cells even if modified
§ Naturally occurring biological material, even if isolated • Microorganisms • Extracts and substances • DNA/RNA sequences
§ Second medical use (PTO accepts, but ANVISA does not)
dannemann.com.br © 2012 Dannemann Siemsen. All rigths reserved. 29
BRAZIL -‐ Access to Brazilian biodiversity
§ Since 2000, mandatory authoriza5on to perform R&D in and to manufacture products derived from plants and animals of the Brazilian biodiversity
§ Indica5on of source of gene5c resource and access authoriza5on number through recent PTO`s office ac5ons based on Norma5ve Acts
§ Relevant fines were applied on companies
Janeth Mora LinkPharma LLC
The Cira Hub Center
Philadelphia, February 27, 2012
Key Regulatory Requirements Brazil
(ANVISA) Mexico
(COFEPRIS) Argen@na (ANMAT)
Bioavailability study (if changes to innovator)
If approved in Reference country
Bioequivalence (with reference product)
If approved in Reference country
Good Manufacturing Prac@ces Inspec@on visit
Stability in Zone IVB
Cer@ficate of Pharmaceu@cal Product (CPP)
Take away Points
� An effective due diligence to develop your own branded generic strategy in Latin America should consider : ¡ Local partnerships ¡ Collaborations with the government ¡ Understanding of markets unmet needs ¡ Innovative manufacturing technology to drive low cost ¡ Local partners are interested in manufacturing rights ¡ Regulatory Process is decentralized ¡ Prior FDA/ EMA approval could be leveraged ¡ Previous research of local patent standing ¡ Limit on royalties on technology transfers/ licensing
transactions
33
February 27-28, 2012
FOR ADDIT IONAL INFORMATION
DR .MUZZ IO@ACUMENB IOPHARMA .COM
WWW.ACUMENB IOPHARMA .COM
Thank you Obrigada
Gracias